January 22, 2018 / 11:43 AM / a year ago

Celgene to buy remaining stake in Juno for $9 billion

Jan 22 (Reuters) - Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

Celgene already owns 9.7 percent in Juno and will offer $87 per share.

Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below